The biggest meta-analysis of the therapeutic effects of NAST in HER2-positive breast cancer (irrespective of the composition of the therapeutic protocol) conducted thus far (78 studies and 25,150 patients were included) computed an overall pCR frequency of 40.9% (20). This evidence concerns the gene ERBB2 and breast carcinoma.